Skip to content

Exploring the Application Value of PET Molecular Imaging Targeting FAP in Oral Squamous Cell Carcinoma

Exploring the Application Value of PET Molecular Imaging Targeting FAP in Oral Squamous Cell Carcinoma

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100050144
Enrollment
Unknown
Registered
2021-08-18
Start date
2021-09-01
Completion date
Unknown
Last updated
2022-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral squamous cell carcinoma

Interventions

68Ga-FAPI&#32
Gold Standard:Pathological examination
and&#32

Sponsors

Zhongnan Hospital of Wuhan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Voluntarily participate and sign the informed consent; 2. Aged > 18 years and< 70 years; 3. Those who are highly suspected of oral cancer in combination with medical history, imaging and other related examinations, who have been diagnosed with oral cancer in the past and are suspected of recurrence after complete remission of oral cancer treatment, who can obtain the results of medical examination and plan surgery; 4. Willing and able to follow schedule visits, treatment plans and laboratory tests; 5. The general biochemical tests (heart, liver, kidney, blood routine) and other indicators in the clinical laboratory were all within the normal range or abnormal without clinical significance.

Exclusion criteria

Exclusion criteria: 1. Patients who plan to become pregnant within 6 months, or are pregnant or breastfeeding; 2. Those who are allergic to experimental drugs, allergic constitution or allergic to multiple drugs; 3. Those who are in poor general condition and whose heart, lung, liver, kidney and other important organ functions cannot tolerate surgery; 4. Before the injection of 18F-FDG, the fasting blood glucose level exceeds 11.0 mmol/L; 5. Weight over 100 kg; 6. Patients with claustrophobia; 7. Those who cannot tolerate lying down for 15-30 minutes; 8. The researchers believe that it is not suitable to participate in this clinical trial; 9. Those who have participated in clinical trials or are participating in other clinical trials within the past month.

Design outcomes

Primary

MeasureTime frame
rang of primary lesions;number of metastatic lesions;

Countries

China

Contacts

Public ContactJiang Yaqun

Zhongnan Hospital of Wuhan University

zn004239@whu.edu.cn+86 15871775482

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026